Charles Ryan: Back here at ASCO 2019, I’m talking with Oliver Sartor from Tulane University, and we’re going to talk about radium, which has been a topic you’ve been discussing and teaching us about for a long time. There’s been a few new developments in the world of radium this year that come from the […]
Sumanta Pal: Welcome to UroToday. My name’s Monty Pal. I’m a GU medical oncologist at the City of Hope Comprehensive Cancer Center. I’m very fortunate today to be joined by my friend/brother/colleague, Petros Grivas, who is a world-famous, world-renowned genitourinary medical oncologist at the University of Washington Cancer Center. Dr. Grivas, welcome. Petros Grivas: Thank […]
Alicia Morgans: Hi. I am delighted to have here with me today, Brenda Martone, a nurse practitioner in medical oncology at Northwestern University and a wonderful colleague of mine. I am thrilled to talk with you today Brenda about clinical trials and how we think about those, how you think about clinical trials and how […]
The aim of this study was to determine clinical recrudescent risk factors of 477 patients with newly discovered nonmuscle-invasive bladder cancer (NMIBC) (Ta-T1) in our hospital, and based on these factors, to establish a recurrence risk prediction model of each NMIBC patient. This study included 477 patients with newly discovered NMIBC (Ta-T1) from January 2012 […]
The availability of new potent systemic therapies for urothelial carcinoma may change the way we use standard chemotherapy perioperatively. In particular, identifying which patients with muscle-invasive bladder cancer (MIBC) would benefit from adjuvant chemotherapy (AC) is compelling. From a multicenter database we selected 950 patients with cT2-4N0M0 MIBC treated with radical cystectomy (RC), with or […]
To determine the comparative effectiveness of primary radical prostatectomy (RP) compared to external bean radiation therapy (EBRT) with androgen deprivation therapy (ADT), or EBRT plus brachytherapy (BT) with or without ADT among Medicare fee-for-service beneficiaries with high-risk prostate cancer, for 10-year, mortality (overall and prostate cancer-specific), complications, health service use, and cost. This population-based cohort […]
To assess cancer detection rates of different target-dependent transperineal magnetic resonance (MR) / ultrasound (US) fusion-guided biopsy templates with reduced number of systematic cores. Single-centre outcome of transperineal MR/US fusion guided biopsies of 487 men with a single target MRI lesion, prospectively collected between 2012 and 2016. All men underwent transperineal targeted biopsy (TB) with […]
Sexual function can be impaired by all prostate cancer treatment modalities, but studies specifically addressing the impact of stereotactic body radiotherapy (SBRT) on sexual function are scarce. To systematically evaluate sexual outcomes in patients treated by SBRT for prostate cancer and determine clinical factors associated with erectile dysfunction (ED). A systematic review of the available […]
Prostate cancer care in the Middle East is highly variable and access to specialist multidisciplinary management is limited. Academic tertiary referral centers offer cutting-edge diagnosis and treatment; however, in many parts of the region, patients are managed by non-specialists with limited resources. Due to many factors including lack of awareness and lack of prostate-specific antigen […]
To evaluate current views on comparing delayed ligature of the dorsal venous complex (D-DVC) with standard ligature of the dorsal venous complex (S-DVC) for safety, urinary control and oncological outcomes during laparoscopic radical prostatectomy. A comprehensive searching of PubMed, Web of science, Embase and the Cochrane Library was made and then we performed a meta-analysis, […]
